Protara Therapeutics, Inc. (TARA)
3.965
+0.02
(+0.63%)
USD |
NASDAQ |
Sep 03, 13:40
Protara Therapeutics Research and Development Expense (TTM) : 52.89M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 52.89M |
| March 31, 2026 | 46.68M |
| December 31, 2025 | 42.27M |
| September 30, 2025 | 38.74M |
| June 30, 2025 | 37.22M |
| March 31, 2025 | 32.85M |
| December 31, 2024 | 31.45M |
| September 30, 2024 | 28.34M |
| June 30, 2024 | 26.49M |
| March 31, 2024 | 27.35M |
| December 31, 2023 | 24.76M |
| September 30, 2023 | 23.29M |
| June 30, 2023 | 20.55M |
| March 31, 2023 | 16.41M |
| December 31, 2022 | 16.56M |
| September 30, 2022 | 15.71M |
| June 30, 2022 | 16.40M |
| March 31, 2022 | 19.21M |
| December 31, 2021 | 21.00M |
| September 30, 2021 | 20.55M |
| June 30, 2021 | 19.21M |
| March 31, 2021 | 15.83M |
| December 31, 2020 | 11.82M |
| September 30, 2020 | 8.898M |
| June 30, 2020 | 7.248M |
| Date | Value |
|---|---|
| March 31, 2020 | 5.779M |
| December 31, 2019 | 3.862M |
| September 30, 2019 | 5.826M |
| June 30, 2019 | 7.082M |
| March 31, 2019 | 8.855M |
| December 31, 2018 | 11.85M |
| September 30, 2018 | 12.40M |
| June 30, 2018 | 20.38M |
| March 31, 2018 | 21.51M |
| December 31, 2017 | 21.69M |
| September 30, 2017 | 22.91M |
| June 30, 2017 | 17.42M |
| March 31, 2017 | 18.77M |
| December 31, 2016 | 18.87M |
| September 30, 2016 | 18.01M |
| June 30, 2016 | 16.25M |
| March 31, 2016 | 14.10M |
| December 31, 2015 | 12.38M |
| September 30, 2015 | 10.68M |
| June 30, 2015 | 9.37M |
| March 31, 2015 | 7.876M |
| December 31, 2014 | 6.432M |
| September 30, 2014 | 5.529M |
| June 30, 2014 | 4.625M |
| March 31, 2014 | 4.163M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.297M |
| Summit Therapeutics, Inc. | 568.74M |
| Kezar Life Sciences, Inc. | 23.12M |
| Clene, Inc. | 11.48M |